170 related articles for article (PubMed ID: 7655134)
1. Amphotericin B toxicity reduced by administration in fat emulsion.
Anderson RP; Clark DA
Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
[TBL] [Abstract][Full Text] [Related]
2. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B--not so terrible.
Bishara J; Weinberger M; Lin AY; Pitlik S
Ann Pharmacother; 2001 Mar; 35(3):308-10. PubMed ID: 11261528
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B infused in 20% lipid emulsion.
Ryan KA
J Intraven Nurs; 1996; 19(3):123-5. PubMed ID: 8788829
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
[TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
7. Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B.
Buckley MS; Anderson CS; Patel SA; Yerondopoulos MJ; Wicks LM; Martin MT
Am J Health Syst Pharm; 2013 Jun; 70(12):1047-51. PubMed ID: 23719882
[TBL] [Abstract][Full Text] [Related]
8. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
Caillot D; Casasnovas O; Solary E; Chavanet P; Bonnotte B; Reny G; Entezam F; Lopez J; Bonnin A; Guy H
J Antimicrob Chemother; 1993 Jan; 31(1):161-9. PubMed ID: 8444659
[TBL] [Abstract][Full Text] [Related]
10. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
[TBL] [Abstract][Full Text] [Related]
11. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
[TBL] [Abstract][Full Text] [Related]
12. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
Moreau P; Milpied N; Fayette N; Ramée JF; Harousseau JL
J Antimicrob Chemother; 1992 Oct; 30(4):535-41. PubMed ID: 1490923
[TBL] [Abstract][Full Text] [Related]
13. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
14. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
[TBL] [Abstract][Full Text] [Related]
15. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
Manfredi R; Chiodo F
Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B.
Leake HA; Appleyard MN; Hartley JP
J Infect; 1994 May; 28(3):319-22. PubMed ID: 8089520
[TBL] [Abstract][Full Text] [Related]
17. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels.
Arning M; Kliche KO; Heer-Sonderhoff AH; Wehmeier A
Mycoses; 1995; 38(11-12):459-65. PubMed ID: 8720196
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
Hasibi M; Jafari S; Manshadi SA; Asadollahi M; Salehi M; Zarch VV; Kouhi A
Ear Nose Throat J; 2017 Feb; 96(2):E18-E22. PubMed ID: 28231371
[TBL] [Abstract][Full Text] [Related]
19. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group.
Am J Med; 1989 Jun; 86(6 Pt 1):668-72. PubMed ID: 2658574
[TBL] [Abstract][Full Text] [Related]
20. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature.
Johnson MD; Drew RH; Perfect JR
Pharmacotherapy; 1998; 18(5):1053-61. PubMed ID: 9758315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
